Finance

Lists
Why is 524494 down ३.५१%?
Dive Deeper
524494:BOM
IPCA Laboratories Ltd
₹ १,८४५.००
-३.५१%
(-६७.२०) 1D
अक्टोबर १६, १५:३०:०० GMT+५:३०  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524494...
Open
₹ १,९१३.९५
High
₹ १,९१३.९५
Low
₹ १,८१२.६०
Mkt. cap
४.६८ खरब
Avg. vol.
२७.९० हजार
Volume
१२.०० हजार
Dividend
०.३३%
Quarterly dividend
₹ १.५०
Ex-dividend date
२०२६ अगस्ट ७
P/E ratio
३५.७४
52-wk high
₹ २,०३९.३०
52-wk low
₹ १,२५२.९५
EPS
₹ ५१.६३
Shares outstanding
१२.६४ करोड
No. of employees
१७ हजार
Open
₹ १,९१३.९५
High
₹ १,९१३.९५
Low
₹ १,८१२.६०
Mkt. cap
४.६८ खरब
Avg. vol.
२७.९० हजार
Volume
१२.०० हजार
Dividend
०.३३%
Quarterly dividend
₹ १.५०
Ex-dividend date
२०२६ अगस्ट ७
P/E ratio
३५.७४
52-wk high
₹ २,०३९.३०
52-wk low
₹ १,२५२.९५
EPS
₹ ५१.६३
Shares outstanding
१२.६४ करोड
No. of employees
१७ हजार
News stories
From web sources and news partners
Profile
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries. Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
About IPCA Laboratories Ltd
CEO-
Employees१७.२ हजार
Founded१९४९ अक्टोबर १९
Headquarters-
Sector-
Websiteipca.com
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
२५.५६ अरब
२३.९२ अरब
२३.८९ अरब
२७.८८ अरब
Cost of goods sold
७.८२ अरब
६.५८ अरब
१०.३१ अरब
७.९७ अरब
Cost of revenue
७.८२ अरब
६.५८ अरब
१०.३१ अरब
७.९७ अरब
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५.३८ अरब
५.४६ अरब
५.५४ अरब
६.०२ अरब
Operating expense
१३.३३ अरब
१३.०९ अरब
९.१७ अरब
१४.३२ अरब
Total operating expenses
२१.१५ अरब
१९.६७ अरब
१९.४८ अरब
२२.२९ अरब
Operating income
४.४२ अरब
४.२६ अरब
४.४१ अरब
५.५९ अरब
Other non operating income
२७.८६ करोड
२०.१९ करोड
-६८.०३ करोड
२५.२६ करोड
EBT including unusual items
३.८९ अरब
४.४६ अरब
४.०२ अरब
५.७४ अरब
EBT excluding unusual items
४.४७ अरब
४.२८ अरब
३.६२ अरब
५.७४ अरब
Income tax expense
१.०८ अरब
८१.९३ करोड
९५.०५ करोड
१.४९ अरब
Effective tax rate
२७.८१%
१८.३९%
२३.६६%
२६.०३%
Other operating expenses
६.९२ अरब
६.५५ अरब
२.५६ अरब
७.२० अरब
Net income
२.८३ अरब
३.२६ अरब
२.९९ अरब
४.०२ अरब
Net profit margin
११.०५%
१३.६४%
१२.५२%
१४.४१%
Earnings per share
१२.३५
१२.०९
१३.३१
१५.८४
Interest and investment income
-
-
३१.७२ करोड
-
Interest expense
-१९.६१ करोड
-१७.६२ करोड
-१९.९९ करोड
-११.८८ करोड
Net interest expenses
-१९.६१ करोड
-१७.६२ करोड
११.७३ करोड
-११.८८ करोड
Depreciation and amortization charges
१.०३ अरब
१.०८ अरब
१.०४ अरब
१.११ अरब
EBITDA
५.४३ अरब
५.१८ अरब
५.३७ अरब
६.५५ अरब
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google एपहरू